Treatment strategies in cervical cancer: treatment of advanced disease

Valdivia, Augusto; Grau-Bejar, Juan Francisco; Garcia-Duran, Carmen; Oaknin, Ana

doi:10.20517/2394-4722.2022.34

Cited by 6 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As these 2 confirmatory trials reinforce ICIs’ position in frontline management of aCC, the search for more agents to the armamentarium in later lines has intensified. Cytotoxic monotherapies such as gemcitabine, vinorelbine, pemetrexed and topoisomerase I inhibitors remain valid options, but are of limited efficacy and lack evidence of conferring OS benefit over best supportive care in this population [ 27 ]. Antibody-drug conjugates (ADCs) have superseded cytotoxics as treatment of choice of aCC after previous platinum-based chemotherapy with or without bevacizumab and ICI.…”

Section: Accmentioning

confidence: 99%

Evolving standards and future directions for systemic therapies in cervical cancer

Ang,

Chan

2024

J Gynecol Oncol

View full text Add to dashboard Cite

Several groundbreaking clinical trials with the potential to transform the management paradigm of both locally advanced and persistent, recurrent, or metastatic cervical cancers have been presented in 2023. This review describes the reported data from INTERLACE and KEYNOTE-A18 in the locally advanced setting, as well as BEATcc, innovaTV 301 and DESTINY-PanTumor02 for advanced disease. The practice implications of their positive results are interpreted in the context of global health considerations, and updated treatment algorithms are proposed. Furthermore, emerging trends in drug development for cervical cancer are discussed. As the routine use of immune checkpoint inhibitors (ICIs) for curative and palliative indications increases in the foreseeable future, patients whose cervical cancers which persist, relapse or progress after prior ICI exposure will represent an area of unmet clinical need and form the key target population for next-generation trials. Future research will help shape oncologists’ approaches in the optimal selection, sequencing and re-treatment or rechallenge of immuno-oncology agents and/or antibody-drug conjugates in women with cervical cancer.

show abstract

Section: Accmentioning

confidence: 99%

Evolving standards and future directions for systemic therapies in cervical cancer

Ang,

Chan

2024

J Gynecol Oncol

View full text Add to dashboard Cite

show abstract

“…However, the efficacy outcomes were globally very poor, with an overall response rate of less than 20%, median progression-free survival of 3.3 months, and median overall survival of 6.7 months. 16 In this adverse scenario arises the clinical development of immune checkpoint inhibitors in the cervical cancer population, based on the aforementioned biological rationale.…”

Section: Role Of Immune Checkpoint Inhibitors For Persistent Recurren...mentioning

confidence: 99%

Advances in immunotherapy in cervical cancer

Grau

Fariñas‐Madrid

Garcia-Duran

et al. 2023

Int J Gynecol Cancer

Self Cite

View full text Add to dashboard Cite

Cervical cancer represents a major public health problem, being the fourth most common cancer in incidence and mortality in women worldwide. Patients with recurrent, persistent, or metastatic disease unsuitable for curative therapeutic approaches have a dismal prognosis. Until recently, these patients were only candidates for cisplatin-based chemotherapy plus bevacizumab. However, the introduction of immune checkpoint inhibitors has revolutionized the treatment of this disease, achieving historical overall survival improvements in both the post-platinum and front-line settings. Interestingly, the clinical development of immunotherapy in cervical cancer is currently advancing to the locally advanced setting, although preliminary efficacy outcomes in this setting have been disappointing so far. Moreover, promising data are emerging from early-phase trials on novel immunotherapy approaches, such as human papillomavirus therapeutic vaccines and adoptive cell therapy. This review summarizes the main clinical trials carried out in the field of immunotherapy in the last several years.

show abstract

“…Thus, there was a high unmet need for novel therapies to improve the dismal prognosis of this particular patient subgroup. 26 …”

Section: Role Of Icis For Persistent Recurrent and Metastatic Disease...mentioning

confidence: 99%

“…Thus, there was a high unmet need for novel therapies to improve the dismal prognosis of this particular patient subgroup. 26 The clinical development of ICI in cervical cancer was initiated in this difficult-to-treat population based on the aforementioned robust biological rationale.…”

Section: Role Of Icis For Persistent Recurrent and Metastatic Disease...mentioning

confidence: 99%

Advances in immunotherapy for cervical cancer

et al. 2023

Self Cite

View full text Add to dashboard Cite

Cervical cancer still represents a major public health problem, being the fourth most common cancer in incidence and mortality in women worldwide. These figures are unacceptable since cervical cancer, an human papillomavirus-related malignancy, is a largely preventable disease by means of well-established screening and vaccination programs. Patients with recurrent, persistent, or metastatic disease unsuitable for curative therapeutic approaches represent a dismal prognosis population. Until recently, these patients were only candidates for cisplatin-based chemotherapy plus bevacizumab. However, the introduction of immune checkpoint inhibitors has revolutionized the treatment landscape of this disease achieving historical overall survival improvements in both the post-platinum and frontline settings. Interestingly, the clinical development of immunotherapy in cervical cancer is currently advancing to earlier stages of the disease, as the locally advanced setting, whose standard of care has not changed in the last decades with still modest outcomes. As more innovative immunotherapy approaches are in clinical early development in advanced cervical cancer, promising efficacy data are emerging that may shape the future of this disease. This review summarizes the main treatment advances carried out in the field of immunotherapy throughout the past years.

show abstract

Treatment strategies in cervical cancer: treatment of advanced disease

Cited by 6 publications

References 37 publications

Evolving standards and future directions for systemic therapies in cervical cancer

Evolving standards and future directions for systemic therapies in cervical cancer

Advances in immunotherapy in cervical cancer

Advances in immunotherapy for cervical cancer

Contact Info

Product

Resources

About